Akeso, Inc. (HKG:9926)
84.35
+0.10 (0.12%)
May 9, 2025, 4:08 PM HKT
Akeso Revenue
In the year 2024, Akeso had annual revenue of 2.12B CNY, down -53.08%. Akeso had revenue of 1.10B in the half year ending December 31, 2024, with 62.96% growth.
Revenue
2.12B CNY
Revenue Growth
-53.08%
P/S Ratio
33.50
Revenue / Employee
764.56K CNY
Employees
2,778
Market Cap
75.71B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 32.49B |
Hansoh Pharmaceutical Group Company | 13.05B |
JD Health International | 61.89B |
WuXi Biologics | 19.87B |
Innovent Biologics | 10.03B |
Alibaba Health Information Technology | 31.39B |
Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |
Sino Biopharmaceutical | 30.72B |
Akeso News
- 11 days ago - Why Is Summit Therapeutics Stock Trading Higher On Monday? - Benzinga
- 11 days ago - China’s Akeso, hailed as biotech’s ‘DeepSeek moment’, falls despite nod for cancer drug - South China Morning Post
- 14 days ago - What's Going On With Summit Therapeutics Stock On Friday? - Benzinga
- 16 days ago - Why Is Summit Therapeutics Stock Soaring On Wednesday? - Benzinga
- 18 days ago - Akeso (9926) Poised for Growth Despite Current Undervaluation - GuruFocus
- 19 days ago - Bullish On Akeso's Ivonescimab, But Valuation And Geopolitical Risks Remain - Seeking Alpha
- 4 weeks ago - Why This Chinese Biotech Could Be Pharma's DeepSeek - Benzinga
- 5 weeks ago - Akeso reports FY results - Seeking Alpha